Couldn't be more confident!Folks!!
Patience is going to pay off!! BET THE FARM!!
Look....the results speak for themselves. Do your DD and compare GAP-107B8 with Gleevecs results against ATC and CML....just 2 types of cancers....
https://jcem.endojournals.org/cgi/reprint/89/5/2127.pdf
Check out the graph on the bottom right hand side of page 3.........took a few read throughs....I'm no MD.....but this is pretty visual.....read all of the Results section...including top of page 4 and look at table 2....
Now....what this says to me in simple terms and has obviously been proven....(Gleevec I believe brought in something like $5.6 Billion in sales alone for Novartis in 2008...it is officially the cure for CML I believe)...that Gleevec worked on cell line K562.....the chart distinctly shows the SURVIVAL RATE of K562 as doses increased....but the other 2....ARO81 and BHT101...also decreased in SURVIVAL RATE but only at doses beyond what could be studied for human trials.
NOW.....
Pretend this was GAP-107B8 chart..............with 56 different cell lines color coded....representing all the different cancers GAP-107B8 was tested against.......the range of uM listed below from 0 - 100...on the left would be the survival rate....as the diagram clearly shows in my example noted above.....
Would we not see that 51 of those 56 CANCER TYPES nose dive at 23uM? Is this not what the results tell us from an independent body...namely NCI????
Folks......we are talking about human trials around the corner.....if not now......its going to be very soon. NCI is coming to Ottawa for a reason......with NCI in their back pocket....the January conference around the corner....licencing deal soon to follow........and a tonne of news in between.....its a race to the finish line!
BY THIS TIME NEXT YEAR...$20 GUARRANTEED....IF NOT MORE!!
Funkyferny
PS. Don't say I didn't tell you soo.....but BUY AS MUCH AS YOU CAN!!!